You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Current Challenges in Child and Adolescent Psychiatry

  • Authors: Rachel Brown, MBBS; Jon E. Grant, MD, JD, MPH; Gregory W. Mattingly, MD; Amanda J. Simonton, PhD, APRN, PMHNP-BC; Kristin Sohl, MD, FAAP
  • CME / ABIM MOC / CE Released: 12/21/2022
  • Valid for credit through: 12/21/2023
Start Activity

  • Credits Available

    Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 2.50 ABIM MOC points

    Nurses - 2.50 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    IPCE: 2.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, neurologists, nurse practitioners (NPs), primary care physicians (PCPs), pediatricians, physician assistants (PAs), nurses, pharmacists, and other healthcare practitioners (HCPs) who provide care to pediatric patients with neuropsychiatric disorders.

The goal of this activity is for learners to be better able to screen, diagnose, and manage pediatric patients with neuropsychiatric and psychiatric disorders.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Impact of the COVID-19 pandemic on the prevalence of and risks for behavioral health disorders in pediatric patients
    • Recent clinical data on emerging and novel interventions for ADHD
    • Recent clinical data on emerging and novel tools for autism spectrum disorder (ASD) screening and diagnosis
    • Regarding the up-to-date evidence on clinical interventions for pediatric patients with ASD
  • Have greater competence related to
    • Implementing best practices in pharmacologic and non-pharmacologic management of obsessive-compulsive disorder (OCD) in adolescent patients
  • Demonstrate greater confidence in their ability to
    • Incorporate interprofessional strategies into adolescent psychiatric care


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Session and Conference Chair

  • Gregory W. Mattingly, MD

    Associate Clinical Professor
    Washington University School of Medicine
    President, Midwest Research Group
    President-Elect
    APSARD - American Professional Society for ADHD and Related Disorders
    St. Louis, Missouri

    Disclosures

    Gregory W. Mattingly, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie, Inc; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium Inc.; Eisai, Inc; Ironshore Pharmaceuticals, Inc.; Intra-Cellular Therapies, Inc; Janssen; Lundbeck, Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax; Rhodes Pharmaceuticals L.P.; Roche; Sage Therapeutics; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, inc.; Takeda; Teva; Tris Pharma, Inc.
    Received grants for clinical research from: AbbVie, Inc.; Alkermes, Inc.; Corium Inc.; Eisai, Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda; Tris Pharma, Inc.
    Contracted researcher for: AbbVie, Inc.; Acadia Pharmaceuticals, Inc.; Alkermes, Inc.; Akili Interactive Labs, inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Inc.; Janssen; Karuna Therapeutics; Lumos Labs; Medgenics; NLS-1 Pharma AG; Redax; Relmada Therapeutics, Inc.; Roche; Sage Therapeutics; Sirtsei Pharmaceuticals, Inc.; Sunovion Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Takeda; Teva Neuroscience, Inc.

Faculty

  • Rachel Brown, MBBS

    Professor and Chair
    Psychiatry and Behavioral Sciences
    The University of Kansas School of Medicine
    Wichita, Kansas

    Disclosures

    Rachel Brown, MBBS, has no relevant financial relationships.

  • Jon E. Grant, MD, JD, MPH

    Professor of Psychiatry
    University of Chicago
    Chicago, Illinois

    Disclosures

    Jon E. Grant, MD, JD, MPH, has the following relevant financial relationships:
    Received grants for clinical research from: Biohaven Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd.

  • Amanda J. Simonton, PhD, APRN, PMHNP-BC

    Clinical Assistant Professor
    School of Nursing
    The University of Texas at Austin
    Psychiatric Nurse Practitioner
    Texas Child Study Center
    Dell Children's Medical Center
    Psychiatric Nurse Practitioner
    CARMA Health
    Austin, Texas

    Disclosures

    Amanda J. Simonton, PhD, APRN, PMHNP-BC, has the following relevant financial relationships:
    Served as an advisor or consultant for: Alkermes Inc. (former); Corium Inc. (former)

  • Kristin Sohl, MD, FAAP

    ​Professor
    Department of Child Health
    Executive Director
    Extension for Community Healthcare Outcomes (ECHO) Autism
    University of Missouri
    Columbia, Missouri

    Disclosures

    Kristin Sohl, MD, FAAP, has the following relevant financial relationships:
    Served as an advisor or consultant for: Cognoa, Inc. (former); Quadrant Biosciences
    Received grants for clinical research from: Cognoa, Inc.

Editor

  • Clinton W. Wright, PharmD, BCPP

    Medical Education Director, Medscape, LLC

    Disclosures

    Clinton W. Wright, PharmD, BCPP, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 2.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 2.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Current Challenges in Child and Adolescent Psychiatry

Authors: Rachel Brown, MBBS; Jon E. Grant, MD, JD, MPH; Gregory W. Mattingly, MD; Amanda J. Simonton, PhD, APRN, PMHNP-BC; Kristin Sohl, MD, FAAPFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/21/2022

Valid for credit through: 12/21/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Unpacking the Impact of COVID-19 on Pediatric Mental Health

Quantifying COVID-19's impact on youth mental health: Where do we stand 2 years later?
Amanda J. Simonton, PhD, APRN, PMHNP-BC

Innovations in ADHD: Updates in Pharmacologic and Nonpharmacologic Therapeutics

How does life change developmentally for individuals with ADHD? Learn this and more from world-renowned experts
Gregory W. Mattingly, MD

Best Practices in OCD Management in Adolescents

Are you up to date on OCD in adolescents? It's more than just handwashing
Jon E. Grant, MD, JD, MPH

Opening the Door to Earlier Recognition: Advancements in the Screening and Diagnosis of Autism Spectrum Disorder

Developmental surveillance: Can you identify abnormalities in social communication?
Kristin Sohl, MD, FAAP

The Management of Autism Spectrum Disorder

Start low and go slow. Did you know that there are higher rates of sides effects and that responses may be unpredictable?
Rachel Brown, MBBS
 

Educational Impact Challenge

The goal of this activity is for learners to be better able to screen, diagnose, and manage pediatric patients with neuropsychiatric and psychiatric disorders.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print